Mosanna Therapeutics, Inc., announced results from its Phase 1 MOSAIC study. MOS118 was safe and well tolerated across all doses, with no serious adverse events reported. These results support progression of the study into patients with OSA. “With these results we can now proceed to evaluate MOS118 in the patients it […]